Given the sustained increase in variants resistant to bamlanivimab alone, and availability of alternative authorized monoclonal antibodies, the U.S. government, in coordination with Eli Lilly, will stop the distribution of bamlanivimab alone starting today, the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response announced. Provider sites will still be able to order bamlanivimab/etesevimab, etesevimab alone to pair with existing stock of bamlanivimab on hand or REGEN COV following existing ordering and reporting procedures.

The Food and Drug Administration Friday updated the health care provider fact sheets for all three monoclonal antibody therapies authorized for emergency use to include information on whether SARS-CoV-2 variants may show resistance to that therapy. 
 

Related News Articles

Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
AHA is providing its latest social media toolkit to help hospitals encourage vaccination against COVID-19. The newest toolkit includes messages and assets…
Headline
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…
Headline
In time for back-to-school health screenings, AHA Aug. 25 released an infographic on strategies that clinicians and the Centers for Disease Control and…